Mhw. Vandepoel et al., MALIGNANT TRANSFORMATION OF MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE AMONG OUT-PATIENTS OF A COMMUNITY-HOSPITAL IN SOUTHEASTERN NETHERLANDS, British Journal of Haematology, 91(1), 1995, pp. 121-125
Patients with a monoclonal gammopathy without evidence of lymphoprolif
erative or plasma cell malignancy within a year are still at risk for
malignant transformation to multiple myeloma, Waldenstrom's macroglobu
linaemia or non-Hodgkin's lymphoma. In a prospective study performed a
t the Mayo Clinic, the cumulative incidence of malignant transformatio
n was 29% in 14 years, We conducted a retrospective study to determine
the frequency of malignant transformation among 334 unselected out-pa
tients with monoclonal gammopathy of undetermined significance (MGUS)
from a community hospital in Southeastern Netherlands. The cumulative
incidence of malignant transformation was 11% in 14 years (95% confide
nce internal 6-17%). The long-term survival of patients with MGUS was
sightly lower than that of the average regional population in a nested
case-control study, presence of a kappa light chain was found to be a
risk factor for malignant transformation (70% of patients who develop
ed malignant transformation compared to 30% of the control group, P <
0.01). Likewise, an initial high gamma globulin level was also found t
o be a risk factor (18.7 g/l v 13.7 g/l in the control group, P < 0.01
). As neither risk factor has been described before, the significance
of these factors for definition of a high-risk group among patients wi
th monoclonal gammopathy remains to be determined.